Visitor information – Everything you need to know about visiting our sites.
Alfred Health research outcomes are published in a wide range of peer reviewed journals.
Search or browse research publications by year, research area, publication type or keyword.
Publication Details
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells
Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ, Fedele PL, Low MSY, Grigoriadis G, Harrison SJ, Strasser A, Roberts AW, Huang DCS, Nolan GP, Gray DHD, Ko ME
(2020), Cell Death Differ, 27(7), 2217-33
Quality audit of the guidelines for the use of RhD immunoglobulin in obstetrics: Are we getting it right?
Glazebrook B, Akers C, Bielby L, Bastin K, Von Wielligh K, Daly J
(2020), AUST NZ J OBSTET GYN, 60(4), 504-8
DOI: 10.1111/ajo.13177
Treatment practice and outcomes in FLT3-mutant acute myeloid leukemia in the pre-midostaurin era: a real-world experience from Australian tertiary hospitals
Chua CC, Grigg A, Singh J, Droogleever MP, Zhang L, Lim A, Fong CY, Ting SB, Schwarer A, Tiong IS, Wei AH
(2020), LEUKEMIA LYMPHOMA, 61(4), 848-54
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
Voso MT, Larson RA, Jones D, Marcucci G, Prior T, Krauter J, Heuser M, Lavorgna S, Nomdedeu J, Geyer SM, Walker A, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte TM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Chen Y, Pallaud C, Du L, Piciocchi A, Ehninger G, Byrd J, Thiede C, Döhner K, Stone RM, Döhner H, Bloomfield CD, Lo-Coco F
(2020), Blood Adv, 4(19), 4945-54
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
Montesinos P, Beckermann BM, Catalani O, Esteve J, Gamel K, Konopleva MY, Martinelli G, Monnet A, Papayannidis C, Park A, Récher C, Rodríguez-Veiga R, Röllig C, Vey N, Wei AH, Yoon SS, Fenaux P
(2020), Future Oncol, 16(13), 807-15
Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia
Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, Klisovic RB, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Gathmann I, Benner A, Pallaud C, Stone RM, Döhner H, Bloomfield CD
(2020), Blood, 135(5), 371-80
New directions for emerging therapies in acute myeloid leukemia: the next chapter
Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD
(2020), Blood Cancer J, 10(10), 107
Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J
(2020), Lancet Haematol, 7(8), e601-12
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, Giai V, Ofran Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators
(2020), NEW ENGL J MED, 383(26), 2526-37
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P
(2020), Blood, 135(24), 2137-45
How I treat acute myeloid leukemia in the era of new drugs
DiNardo CD, Wei AH
(2020), Blood, 135(2), 85-96
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW
(2020), NEW ENGL J MED, 383(7), 617-29
notuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia
Ryland GL, Barraclough A, Fong CY, Fleming S, Bajel A, Hofmann O, Westerman D, Grimmond S, Blombery P
(2020), Brit J Haematol, 191(1), 123-6
DOI: 10.1111/bjh.16949
Cotargeting BCL-2 and MCL-1 in high-risk B-ALL
Moujalled DM, Hanna DT, Hediyeh-Zadeh S, Pomilio G, Brown L, Litalien V, Bartolo R, Fleming S, Chanrion M, Banquet S, Maragno AL, Kraus-Berthier L, Schoumacher M, Mullighan CG, Georgiou A, White CA, Lessene G, Huang DCS, Roberts AW, Geneste O, Rasmussen L, Davis MJ, Ekert PG, Wei A, Ng AP, Khaw SL
(2020), Blood Adv, 4(12), 2762-7
Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup
Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A
(2020), Clin Pharmacokinet, 59(2), 245-56
The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation
Brennan Y, Parikh S, McRae S, Tran H
(2020), Haemophilia, 26(3), 529-35
DOI: 10.1111/hae.13970
Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism
Lim MS, Nandurkar D, Jong I, Cummins A, Tran H, Chunilal S
(2020), J THROMB THROMBOLYS, 49(2), 220-7
Risk Stratification of Acute Pulmonary Embolism and Determining the Effect on Chronic Cardiopulmonary Complications: The REACH Study
Stevens H, Fang W, Clements W, Bloom J, McFadyen J, Tran H
(2020), TH Open, 40(1), e45-50
Ischaemic stroke and transient ischaemic attack on anticoagulants: outcomes in the era of direct oral anticoagulants
Valente M, Leung S, Wu P, Oh DH, Tran H, Choi PMC
(2020), Intern Med J, 50(1), 110-3
DOI: 10.1111/imj.14652
Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities
Stevens H, Peter K, Tran H, McFadyen J
(2020), J Clin Med, 9(5), 1582
DOI: 10.3390/jcm9051582